This is a nonrandomized, open-label treatment protocol for patients with advanced renal cell carcinoma (RCC) who are not eligible for, or who do not have access to, other clinical trials with sorafenib. Patients will be treated with 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC.

Ages Eligible for Study:  15 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Patients with advanced (unresectable, recurrent or metastatic) RCC
• Patients reasonably likely to benefit from treatment with sorafenib as a single agent therapy
• Patients with an ECOG performance status of 0-2
• Patients who will not require other systemic anticancer therapy (except for bisphosphonates) while taking sorafenib
• Patients with vascular diseases such as wet macular degeneration, vasculitis, or new peptic ulcer, may be enrolled but require close monitoring in accordance with established medical practice.

Exclusion Criteria:

• Patients who are currently enrolled in, are eligible for, or have access to, any other sorafenib clinical trial
• Patients who have participated in any other sorafenib trial.
• Patients who have had prior therapy with investigational agent(s) within the last four weeks prior to study entry
• Life expectancy of less than two months
• Patients with cardiac arrhythmias greater than grade 1 NCI CTCAE, Version 3.0.
• Patients with active coronary artery disease or ischemia
• Patients with Child-Pugh class C hepatic impairment
• Patients with severe renal impairment or who require dialysis.
• Patients with active uncontrolled hypertension
• Patients with recent or active bleeding diathesis